ELI LILLY AND COMPANY Operating Lease, Liability, Noncurrent
ELI LILLY AND COMPANY (LLY) had Operating Lease, Liability, Noncurrent of $1.14 billion as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-02-12
- 2025-12-31: Operating Lease, Liability, Noncurrent $1.14B.
- 2024-12-31: Operating Lease, Liability, Noncurrent $971.00M; Operating Lease, Liability, Noncurrent as first filed $970.90M.
- 2023-12-31: Operating Lease, Liability, Noncurrent $948.50M.
- 2019-12-31: Operating Lease, Liability, Noncurrent $486.70M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2025-12-31 | $1.14B 10-K · filed 2026-02-12 | |
| 2024-12-31 | $971.00M 10-K · filed 2026-02-12 | $970.90M 10-K · filed 2025-02-19 |
| 2023-12-31 | $948.50M 10-K · filed 2025-02-19 | |
| 2019-12-31 | $486.70M 10-K · filed 2020-02-19 | |
| 2019-09-30 | $485.20M 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $503.30M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $508.20M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $0.00 10-Q · filed 2019-10-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |